Symposium

Serum neurofilament light: A biomarker for disease activity in MS

1920 1080 Mea Holm, PhD

How close are we to establishing a reliable liquid biomarker for detecting disease onset, progression and treatment response in multiple sclerosis? According to Dr Peter Calabresi (Johns Hopkins, USA) at…

read more

The EAN President’s take on medical education

1024 625 Mea Holm, PhD

At the recent EAN 2018 congress, we met with Professor Franz Fazekas to discuss important advances and ongoing initiatives in medical education and continuous learning for neurologists. Prof. Fazekas is…

read more

Headaches and new ways to crush them

1800 1195 Mea Holm, PhD

At the ‘conference highlights’ session of the 2018 EAN meeting, Professor Isabel Pavão Martins presented a summary of the most groundbreaking research in the field of migraine. This highly burdensome…

read more

Rasagiline add-on treatment may offer hope to fast-progressing ALS patients

8001 4501 Mea Holm, PhD

At the ‘late breaking’ session of the EAN 2018 congress, Professor Albert Ludolph from Ulm University (Germany) unveiled the results of a recent double-blind, randomised Phase II trial of rasagiline…

read more

Revolutionary therapies could make spinal muscular atrophy a distant memory

1200 675 Peter Stevenson, PhD

Cutting-edge molecular and genetic therapies for neurogenic disorders took centre stage at the EAN congress, with novel therapies showcased for the treatment of spinal muscular atrophy (SMA) – a severe…

read more

The many faces of progressive supranuclear palsy

1200 800 Mea Holm, PhD

Progressive supranuclear palsy (PSP)—a neurodegenerative disease characterized by tau pathology—can have a variety of clinical presentations, delegates heard at an EAN 2018 forum talk delivered by Prof. Günther Höglinger from…

read more

PML risks linked to MS drug duration

1200 797 Peter Stevenson, PhD

Development of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients is linked to treatment medications, not the MS itself, delegates heard at the recent Consortium of Multiple Sclerosis Centers…

read more

New app aims to facilitate cognitive screening of MS patients

3008 2008 Mea Holm, PhD

Dr. Stephen Rao from the Cleveland Clinic (Ohio, USA) presented a new tablet-based screening method for cognitive dysfunction at the Consortium of Multiple Sclerosis Centers (CMSC) annual meeting in Nashville,…

read more

“Ask the audience”: Stroke debates feature at ESOC 2018

1600 2400 Peter Stevenson, PhD

Controversies in stroke were laid bare at the recent European Stroke Organisation Conference (ESOC) in Gothenburg, Sweden, in a special session that saw experts rallying to convince the audience of…

read more

Solriamfetol improves wakefulness in narcolepsy patients

1920 1280 Lutz Achtnichts, MD

This year’s American Academy of Neurology (AAN) meeting featured results of a randomised, placebo-controlled phase III study evaluating the safety and efficacy of solriamfetol for the treatment of excessive sleepiness (ES) in…

read more
Brainwork is supported by unrestricted grants from: